Cell Culture

项目SUMIVIARY(请参阅说明)： 细胞培养技术在现代癌症研究中起着至关重要的作用。细胞培养设施(CCF)是一个定制的付费服务设施，提供专业知识、技术支持、试剂、设备、液氮存储和培训，以提高Fox Chase癌症中心(Fccc)实验室使用哺乳动物细胞培养的有效性和效率。该基金提供技术援助和咨询服务，包括组织培养技术、中央液氮银行、 服务包括支原体筛查、定制和标准培养基及补充剂的制备、胎牛血清的性能测试、细胞繁殖，以及为小鼠胚胎干细胞(ES)的转基因和培养提供技术支持和用品。CCF的主要努力包括实施具有技术挑战性的技术，例如从患者或动物组织建立原代细胞培养 通过样品、杂交瘤融合和克隆服务产生单抗，并建立基因“敲除”或“敲入”胚胎干细胞以产生基因操纵的小鼠。自上次审查以来，该中心为CCSG支助的共享资源设立了一个理事机构，称为设施家长监督委员会(FPOC)。FPOC在2008年建议CCF将 杂交瘤设施，它以前被批准为独特的CCSG设施。这一合并通过将合并后的员工集中安置在一起，提高了运营效率。通过减少2.05 FTE的总工作人员，以及减少CCSG的总体要求，已经实现了经济效益。 合并后的中央支助事务厅的预算请求比上次审查时为先前两个不同核心核准的合并数额少了19 724美元。2009年，该机制向47名调查人员提供了经同行审查的资金。 该中心的所有五个CCSG研究项目都提供了服务。经同行评审、资助的研究占2009历年CCF使用量的95.3%。根据FPOC进行的年度质量调查，该设施在教师用户中享有很高的评价，并被评为“优秀到优秀” 在最近一次CCSG审查中的评级。在过去五年，关爱基金服务的需求持续旺盛。 重要的是，该机制为fccc社区提供了宝贵的现场专业知识，用于制定一系列既定的细胞培养方案、在设计和评估实验方面进行咨询、培训细胞培养方法、高质量的培养液和补充剂，以及以具有成本效益的方式提供适应性援助。

PROJECT SUMIVIARY (See instructions): Cell culture technology plays an essential role in modern cancer research. The Cell Culture Facility (CCF) serves as a customized pay-for-service Facility that provides expertise, technical support, reagents, equipment, liquid nitrogen storage, and training to increase the effectiveness and efficiency of using mammalian cell culture in Fox Chase Cancer Center (FCCC) laboratories. This Facility provides technical assistance and consultation services in tissue culture techniques, centralized liquid nitrogen banking, mycoplasma screening services, the preparation of custom and standard culture media and supplements, performance testing of fetal bovine serum, cell propagation, and technical support and supplies for mouse embryonic stem (ES) cell transfection and culture. Major efforts by the CCF include carrying out technically challenging techniques, such as the establishment of primary cell cultures from patient or animal tissue samples, hybridoma fusion and cloning services to generate monoclonal antibodies, and establishing gene "knockout" or "knock-in" Embryonic Stem (ES) cells to generate genetically manipulated mice. Since the last review the Center established a governing body for the CCSG supported Shared Resources called the Facility Parent Oversight Committee (FPOC). The FPOC recommended in 2008 that the CCF incorporate the Hybridoma Facility, which was previously approved as a distinct CCSG Facility. This merger has provided operational efficiencies by centrally locating the merged staff. Economic efficiencies have been achieved by reducing total staff by 2.05 FTE, and by presenting a reduced overall request from the CCSG. The merged CCSG budget request is $19,724 less than the combined levels approved for previously two distinct cores at the last review. In 2009, the Facility served 47 investigators with peer-reviewed funding. Service was provided to all five of the Center's CCSG Research Programs. Peer-reviewed, funded research accounted for 95.3% of CCF usage in calendar year 2009. Based on an annual quality survey administered by the FPOC, the Facility is highly regarded among faculty users, and received an "Outstanding to Excellent" rating at the last CCSG review. In the past five years, the demand for CCF services has remained strong. Importantly, the Facility supplies the FCCC community with valuable on-site expertise for a host of established cell culture protocols, consultation in the design and evaluation of experiments, training in cell culture methodologies, high quality culture media and supplements, and adaptable assistance delivered in a cost-effective manner.